PressJune 16, 2023 Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS
PressJune 14, 2023 Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
PressJune 14, 2023 PharmAla Biotech announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000
PressJune 14, 2023 Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
PressJune 12, 2023 Apex Labs Receives Approval for US-Based Secondary GMP Psilocybin Supplier by Health Canada
PressJune 9, 2023 Numinus to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
PressJune 7, 2023 Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
PressJune 7, 2023 PSYC’s Psychedelic Spotlight Continues Ascent as a Top-Ranking Multimedia Platform for the Psychedelics Sector
PressJune 7, 2023 Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120
PressJune 7, 2023 Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
PressJune 5, 2023 Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
PressJune 5, 2023 Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
PressJune 5, 2023 Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023
PressJune 1, 2023 Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact
PressJune 1, 2023 Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
PressJune 1, 2023 COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer
